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Leonurine and ischaemic heart diseases Ischaemic heart diseases, especially acute myocardial infarction (MI), remain the leading cause of death all over the world [2] . Hypoxia is considered to be one of the important features of ischaemia. Liu et al. [3] have investigated the mechanisms of action of leonurine in hypoxic neonatal rat cardiomyocytes and infarcted rat heart, finding that leonurine significantly increased the viability of cardiomyocytes injured by hypoxia and decreased pro-apoptotic genes Bax and Fas, whereas anti-apoptotic genes Bcl-2 and Bcl-xl expression was upregulated. The anti-oxidant enzymes superoxide dismutase and catalase can also be induced by leonurine. Xin et al. [4] [5] [6] also reported that leonurine attenuated doxorubicin (DOX)/H₂O₂-induced apoptosis and intracellular Ca 2+ in H9c2 cells by increasing anti-oxidant and anti-apoptotic ability, and protecting mitochondrial function. Correspondingly in vivo, leonurine has antioxidative and antiapoptotic effects to reduce myocardial injury during MI [7] . In addition, leonurine improved cardiac function by activating the phosphatidylinositol 3-kinase/Akt signalling pathway and upregulating survivin and vascular endothelial growth factor (VEGF) expression, which may contribute to its anti-apoptotic effects during myocardial infarction [8] .
Xin et al. [9] found that leonurine could reduce I Ca,L , and the LTCCα 1C subunit down-regulation might contribute to altered calcium handling in leonurine-treated cardiomyocytes. Leonurine at 100 μM shortened the action potential duration in a dose-dependent manner. Leonurine up to 200 μM had no significant effect on the Na + (I Na ) and K + currents (I K ), but depressed the L-type Ca 2+ current (I Ca,L ), the same result as shown by RT-PCR and Western blot assays for the transcription and protein expression levels of L-type calcium channels (Cav1.2) in primary cultured neonatal myocytes.
Furthermore, 3,5-dimethoxy-4-(2-amino-3-prop-2-ynylsulfanylpropionyl)-benzoic acid 4-guanidino-butyl ester (1) was designed as a novel leonurine-SPRC conjugate. The combination of leonurine and S-propargyl-L-cysteine (SPRC), a cysteine analog, could be readily hydrolyzed to release bioactive leonurine and SPRC and improve the pharmacological efficiency. Only a lower molar concentration (10-fold less than leonurine required and 100-fold less than SPRC required) of 1 could protect neonatal rat ventricular myocytes against hypoxia-induced damage, the mechanism of which is related to improve hydrogen sulfide production, antioxidative stress and anti-apoptosis to some degree [10] .
Again, the novel leonurine-cysteine analog conjugates 3,5-dimethoxy-4-(2-amino-3-prop-2-ynylsulfanyl-propionyl)-benzoic acid 4-guanidino-butyl ester (1a), 3,5-dimethoxy-4-(2-animo-3-allysulfanyl-propionyl)-benzoic acid 4-guanidino-butyl ester (1b) and 3,5-dimethoxy-4-(3-(2-chlorocarbonyl-ethyldisulfanyl)-propionyl)-benzoic acid 4-guanidino-butyl ester (2) have been designed, synthesized and their biological evaluation reported. All of them had cardioprotective effects. In particular, the biological activity of 1a was higher than 1b and 2, and could also modulate H 2 S production. On the other hand, 1a was able to increase SOD and CAT activity, decrease MDA and ROS levels, protect some cell organs and regulate apoptosis-associated genes and proteins expression (Bcl-2 and Bax) via the caspase-3 pathway at the molecular level as a result of myocardial protection. These results indicated that 1a had the potential to be a new class of multifunctional anti-myocardial ischemia agent. Most importantly, these results revealed that this type of leonurine-cysteine analog conjugate should be further designed and modified in future [11] .
In fact, it is important to note that leonurine protects the heart in diverse ways. It can inhibit intracellular reactive oxygen species (ROS) and mitochondria dysfunction, increase phosphorylation of Akt, and further prevent cytochrome c, inflammatory cytokine release and Bcl-2/Bax ratio down-regulation. This can attenuate caspase activation and exert anti-apoptotic, anti-oxidant, and antiinflammatory effects, which may be an important pathway in mediating cardioprotection. In addition, leonurine increases hypoxia-inducible factor (HIF)-1 expression and triggers vascular endothelial growth factor (VEGF), which also contributes to cardioprotection. The cardioprotective mechanisms of leonurine are summarized in Figure 2 . 
Leonurine and atherosclerosis
Atherosclerosis, an inflammatory and progressive vascular disorder, continues to be the major cause of mortality and morbidity in the world [12] . Several probable mechanisms for atherosclerosis, such as inflammation and oxidative stress, have been cited as leading to cerebro-cardiovascular diseases. This pathological process of atherosclerosis is involved with various chemical mediators including ICAM-1, VCAM-1, IL-6, TNF-α, MCP-1, iNOS and MMP-9 [13, 14] . Zhang et al. [15] have reported that leonurine can prevent the early pathogenesis of atherosclerosis via modulating vascular inflammation. To be specific, leonurine suppressed TNF-α-induced monocyte-endothelium interactions by downregulating ICAM-1 and VCAM-1 expression. This effect was mediated by inhibition of intracellular ROS generation and p38 mitogenactivated protein kinase (MAPK) activation, which led to the inhibition of IκBα degradation and suppression of nuclear factor (NF)-κB activation.
Then Pang et al. [16] studied the effects of extracts of Herba Leonuri on the contraction of the isolated rat aorta. Leonurine pretreatment had vasodilator activities in rat phenylephrine induced isolated aorta, but an aqueous extract of Herba Leonuri enhanced phenylephrine-induced contractions. The recovery results revealed that different concentrations of leonurine used may contribute to this discrepancy between leonurine and the aqueous extract of the crude drug. Leonurine inhibits vascular smooth tone and induces concentration-dependent and endothelium-independent relaxation of phenylephrine-pretreated rat aortic arterial rings, the mechanism of which was probably the inhibition of Ca 2+ influx through both voltage-dependent and receptor-operated channels, as well as the inhibition of mobilization of intracellular Ca 2+ [17] .
Leonurine and stroke
Stroke is the second most common cause of death and the major cause of acquired adult disability worldwide [18] . To date, thrombolysis is the only current effective available stroke therapy. Given its risk of intracranial hemorrhagic transformation, only 5% of stroke patients can take thrombolysis therapy [19] . Loh et al. [20] selected middle cerebral artery occlusion as the model in vivo and found that leonurine pretreatment could reduce infarct volume, improve neurological deficits in stroke groups, increase activities of the antioxidant enzymes superoxide dismutase and glutathione peroxidase, and decrease levels from the lipid peroxidation marker malondialdehyde. Besides, leonurine could also inhibit mitochondrial reactive oxygen species production and adenosine triphosphate biosynthesis. These results clearly demonstrated that leonurine has a preventive action against ischemic stroke via exerting antioxidant effects and regulating mitochondrial function.
Qi et al. [21] reported the neuroprotective effect of synthetic leonurine on nerve cells in an ischaemic stroke model through improving neurological outcome and reducing ischemia/reperfusion (I/R)-induced cerebral infarction. Leonurine decreased reactive oxygen species (ROS) level in mitochondria isolated from the ischemic cortex which was increased by MCAO, markedly decreased Bax and increased Bcl-2 expression. Then, a limited outflow of cytochrome C from mitochondria, restored mitochondrial membrane potential, and attenuation of mitochondrial membrane swelling could also be observed in the leonurine treated group.
Furthermore, Liu et al. [22] reported that leonurine (7.5 and 15 mg/kg) significantly alleviated neurological deficits, decreased brain water content and infarct volume after ischemic stroke via increasing activities of UCP4, SOD, CAT and Bcl-2, decreased MDA and Bax levels, and ameliorated ultrastructure of mitochondria in experimental stroke.
Leonurine and neurodegenerative diseases
Neurodegenerative diseases are defined as the progressive loss of structure or function of neurons, including their death. Parkinson's disease (PD), one of the common manifestations of neurodegeneration, is characterized pathologically by selective loss of dopaminergic neurons in the substantia nigra pars compacta coupled with the accumulation of Lewy bodies. Nowadays, there is a lot of evidence that shows that the accumulation of modified proteins and degeneration of dopaminergic neurons are associated with oxidative stress and apoptosis [23, 24] . Oxidative stress (OS) leads to free radical-induced proteins and DNA injury, inflammation, and subsequent cellular apoptosis [25] ; reactive oxygen species (ROS) have been reported to be involved in the apoptotic process found in PD [26, 27] . Shi et al. [28] have found that the neuroprotective effects of SCM-198, also named leonurine, protected against 6-OHDA-induced toxicity in vivo and in vitro by inhibiting oxidative stress and apoptosis. Specifically, SCM-198 Another common neurodegeneration, Alzheimer's disease (AD), is characterized by cerebral deposition of senile plaques composed of amyloid-β (Aβ) peptides, intraneuronal neurofibrillary tangles originating from hyperphosphorylation of tau protein, loss of neurons and neuroinflammation [29] [30] [31] . Mounting evidence shows that inflammation plays a crucial role in AD progression and microglias, primary immune cells of the brain, contribute largely to the neuroinflammatory responses [32] .
Recently, Hong et al. [33] reported that SCM-198 is neuroprotective and anti-inflammatory both in Aβ 1-40 -injected rats and over activate microglia by inhibition of NF-κB activation and cJun N-terminal kinase (JNK) pathways. In vitro, SCM-198 could reduce nitric oxide (NO), TNF-α, IL-1β and IL-6 expressions resulting in less neuron loss, decreased phosphorylation of tau and extracellular signal-regulated kinase (ERK) in neurons and directly protected against Aβ 1-40 -induced neuronal death and lactate dehydrogenase (LDH) release in primary cortical neurons. In vivo, SCM-198 significantly enhanced cognitive performances of rats 12 days after intrahippocampal injections of aged Aβ 1-40 peptides in the Morris water maze (MWM), accompanied by less hippocampal microglial activation, decreased synaptophysin loss and phosphorylation of ERK and tau.
Leonurine and diabetes
Diabetes mellitus is a potentially life-threatening disease [34] and approximately 90% of those suffering have Type 2 diabetes, which is usually accompanied by serious complications causing damage to eyes and kidneys, as well as the nervous and cardiovascular systems [35, 36] . Early evidence suggests that low-grade inflammation is involved in the pathogenesis of Type 2 diabetes. Huang et al. [37] reported that SCM-198 may be a prospective agent for prevention and/or moderation of Type 2 diabetes progress. Treatment with SCM-198 (200 mg/kg of body weight) for 3 weeks significantly reduced the fasting blood glucose level and increased the plasma insulin concentration in db/db mice, as well as lowering the plasma TAG (triacylglycerol) concentration and increasing the HDL (highdensity lipoprotein)-cholesterol concentration. Moreover, SCM-198 could regulate the transcription of the hepatic glucose metabolic enzymes, including GK (glucokinase), G6Pase (glucose-6-phosphatase) and PEPCK (phosphoenolpyruvate carboxykinase) via an Akt-dependent pathway. The pro-inflammatory mediators, including TNF-α (tumor necrosis factor-α), IL (interleukin)-6, IL-1β, degradation of IκBα and activation of NF-κB were reversed by SCM-198 treatment in the db/db mice. The results obtained provide the first evidence that SCM-198 exhibits anti-inflammatory activity and ameliorates diabetic symptoms via inhibiting the NF-κB/IKK (IκB kinase) pathway.
Leonurine and chronic kidney disease
Chronic kidney disease (CKD), a major cause of end-stage renal disease (ESRD), is defined as a decreased glomerular filtration rate and/or increased urinary albumin excretion [38, 39] . One of the characteristic features of CKD is kidney fibrosis, which is involved with inflammatory reactions and oxidative stress [40, 41] . Cheng et al. [42] reported that leonurine ameliorated kidney fibrosis via suppressing TGF-β/Smad3 and NF-κB signaling pathways in UUO (unilateral urethral obstruction, UUO) mice, which featured renal tubulointerstitial fibrosis and inflammation, and is a candidate renoprotective compound for kidney fibrosis. Pretreatment with leonurine abolished fibronectin expression before urethral obstruction, suppressed α-SMA expression and type I/III collagen and down-regulated vimentin. Leonurine also modified the cytokine expression of TGF-β, TNF-α, IL-6 and IL-1β and suppressed the phosphorylation of Smad3 and NF-κB, and inactivated the signaling pathways associated with the progression of kidney inflammatory response.
Acute kidney injury (AKI), another kind of CKD [43, 44] , is associated with Gram-negative bacterial infection and remains a significant cause of morbidity and mortality in patients [45] [46] [47] . Xu et al. [48] have examined the effect of leonurine on lipopolysaccharide (LPS)-induced AKI in mice. Leonurine protected against LPS-induced AKI, improved animal survival and maintained the redox balance by down-regulation of TNF-α, IL-1, IL-6, IL-8, and KIM-1 expression, and the inhibition of phosphorylation of IκBα and p65 translocalization. Leonurine may suppress NF-κB activation and inhibit pro-inflammatory cytokine production via decreasing cellular ROS production.
Leonurine and other diseases
Kong et al. [49] reported that leonurine was the uterotonic principle of Herba Leonuri in vivo and in vitro. Leonurine, stimulating muscles from isolated mice uteruses, significantly increased the strength and frequency of contraction and caused relaxation of the rat portal vein [50, 51] . Besides, Li et al. [52] reported that leonurine hydrochloride (LH), a synthetic compound, increased uterine contractions in rats with incomplete abortions by modulating the ET receptor-mediated signal pathway.
Osteoporosis is characterized by low bone mass which results from either overactive osteoclastic bone resorption or underactive osteoblastic bone formation, leading to an increased risk of fractures [53, 54] . Yuan et al. [55] reported that leonurine hydrochloride(LH) inhibited osteoclastogenesis and prevented osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways. In RAW 264.7 cells and mouse bone marrow monocytes (BMMs), LH suppressed RANKL-induced osteoclastogenesis, actin ring formation and bone resorption and attenuated RANKL-induced NF-κB signaling by inhibiting the phosphorylation and degradation of IκBα and NF-κB p65 nuclear translocation. LH inhibited the RANK-TRAF6 association triggered by RANKL binding and the phosphatidylinositol 3-kinase (PI3K)/Akt axis, and attenuated the RANKL-stimulated expression of osteoclast-related genes, including NFATc1, tartrate resistant acid phosphatase (TRAP), cathepsin K, and osteoclast-associated receptor (OSCAR). In vivo, LH administration attenuated osteoclast activity and prevented bone loss caused by estrogen deficiency in mice.
Bovine mastitis, defined as inflammation of the mammary gland, is considered to be the most frequent and costly production disease in dairy cattle worldwide [56] . Recently, Song et al. [57] utilized a mouse mastitis model to study the effect of leonurine on LPSinduced mastitis. Leonurine significantly alleviated LPS-induced histopathological changes, downregulated the levels of proinflammatory cytokines TNF-α, IL-6, upregulated the level of antiinflammatory cytokine IL-10, and inhibited the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Further study revealed that leonurine inhibited the expression of Toll-like receptor 4 (TLR4) and the activation of nuclear factor-kappaB (NF-κB) and phosphorylation of p38, extracellular signal-regulated kinase (ERK), and Jun N-terminal kinase (JNK). Thus, leonurine may be a potential agent for mastitis therapy.
Summary
Leonurine, a unique alkaloid, that has received more attention than any other compound in Herba Leonuri [58] , exerts several pharmacological effects, such as a uterotonic action, antiplatelet aggregation, inhibition of vascular contractile responses, analgesic activity, as well as effects on the heart and the circulatory system [59, 60] . Leonurine is also responsible for a wide variety of biological activities, including anti-apoptotic, anti-oxidant and antiinflammatory [3, 6, 61, 62] . Considering that the effect of leonurine in cardiovascular field is mediated by different mechanisms, it was possible to be studied as a new drug.
To date, beneficial pharmacological effects of leonurine have been demonstrated, but most of the research has been limited to the cell and animal levels. All this poses intriguing questions relating to the safety and effectiveness of leonurine. From a clinical point of view, it is important that more basic and clinical experiments should be put into effect to provide a more theoretical basis for the practical application of leonurine.
